‌

US Patent 11274136 Acylated glucagon analogue

Patent 11274136 was granted and assigned to Zealand Pharma A/S on March, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Zealand Pharma A/S

0

Current Assignee

Zealand Pharma A/S

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Leo Thomas0

Dieter Wolfgang Hamprecht0

Ditte Riber0

Jakob Lind Tolborg0

Date of Patent

March 15, 2022

0

Patent Application Number

164107360

Date Filed

May 13, 2019

0

Patent Citations

US Patent 10093713 GIP-GLP-1 dual agonist compounds and methods

US Patent 10004786 Acylated glucagon analogues

US Patent 10100097 GIP-GLP-1 dual agonist compounds and methods

Patent Primary Examiner

0

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11274136 Acylated glucagon analogue

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.